Please assess the completion status of the following clinical trial:

Trial Title: Finasteride for Chronic Central Serous Chorioretinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Participant must have chronic Central Serous Chorioretinopathy (CSC) in at least one eye as defined by all of the following criteria. This eye will be referred to as the study eye.~* The presence of subretinal fluid, as determined by optical coherence tomography (OCT), AND~* The subretinal fluid must have been present for at least three months or recurrent in cases of chronic CSC/diffuse retinal pigment epitheliopathy, AND/OR~* The presence of characteristic fluorescein angiographic or autofluorescence features of CSC, such as one or more pinpoint leaks and/or diffuse retinal pigment epitheliopathy noted on fluorescein or descending tract lesions on autofluorescence.~* Participant must have a steady fixation in the study eye.~* Participant must have media clear enough in the foveal or parafoveal area in the study eye for good quality photographs.~* Participant must have visual acuity between 20/25 and 20/400 in the study eye.~EXCLUSION CRITERIA:~* Participant has evidence of choroidal neovascularization (CNV) in the study eye.~* Participant is expected to need ocular surgery in the study eye during the first three months of the study.~* Participant has had photodynamic therapy (PDT) or focal laser treatment in the study eye within three months prior to enrollment or is expected to need PDT or focal laser treatment in the study eye during the first three months of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Finasteride 5 mg (Type: EXPERIMENTAL): Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).